Covista Tops Q1 FY2027 Estimates and Lifts Full-Year Guidance; CFO Phelan Set to Retire
CVSA sits 55% above its 52-week low of $86.97.
Summary
Covista beat Q1 FY2027 revenue and adjusted EPS estimates and raised full-year guidance, while announcing CFO Robert Phelan's planned retirement and a 25 bps cut to its Term Loan B margin.
Key Events · Earnings and Guidance · CVSA
-
Q1 FY2027 Beat and Guidance Raise
Revenue of $511.5 million rose 10.7% YoY and adjusted EPS of $2.19 rose 25.1% YoY; FY2027 revenue guidance was raised to $2,060-$2,095 million and adjusted EPS to $9.00-$9.20.
-
Enrollment Growth Streak Continues
Total enrollment of 104,713 rose 7.6% YoY, marking the 13th straight quarter of growth, with Walden up 12.8% to a record 58,881 students.
-
CFO Retirement Announced
CFO Robert Phelan will retire after nearly seven years, remaining in the role until a successor is named; an active search is underway.
-
Debt Repriced and Buybacks Funded
The $510 million Term Loan B was repriced 25 bps lower to SOFR plus 2.00%, and $84 million of shares were repurchased in Q1, leaving net leverage at 0.5x.
Analysis · CVSA · Trade & Services
Covista opened fiscal 2027 with revenue of $511.5 million, up 10.7% YoY, and adjusted EPS of $2.19, up 25.1% YoY, then lifted full-year revenue guidance to $2,060-$2,095 million and adjusted EPS to $9.00-$9.20. Enrollment rose for a 13th consecutive quarter to 104,713 students, and adjusted EBITDA climbed 17.1% to $131.2 million. Governance is the offsetting item: CFO Robert Phelan is retiring after nearly seven years, staying on until a successor is named while an active search runs. On the balance sheet, the company repriced its $510 million Term Loan B, cutting the margin 25 basis points to SOFR plus 2.00%, and repurchased $84 million of stock in the quarter, leaving net leverage at 0.5x.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CVSA was trading at $134.66 on NYSE in the Trade & Services sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $86.97 to $152.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.